HOUSTON--(BUSINESS WIRE)--Saranas, a medical device company with a cutting-edge technology for real-time detection and monitoring of internal bleeding during endovascular procedures, placed first runner-up at the Cardiovascular Research Technologies (CRT) competition on March 6, 2018, in Washington, D.C.
“We are extremely honored that our Early Bird™ Bleed Monitoring System has been recognized as a top cardiovascular innovation by the esteemed CRT committee,” Saranas President and CEO Zaffer Syed said. “This acknowledgment substantiates our team’s goal of delivering a solution that has the potential to significantly reduce bleeding complications and improve clinical outcomes in patients undergoing endovascular procedures.”
The Early Bird includes a vascular access sheath with embedded sensors that are designed to detect and monitor bleeding from a blood vessel accidentally injured during endovascular procedures, such as a transcatheter valve replacement, large bore hemodynamic support device placement, or other complex cardiac interventions, where the femoral artery or vein is used to gain vascular access to the heart. The technology was invented at the Texas Heart Institute.
Saranas Chief Medical Officer Dr. Philippe Généreux said, "The Early Bird Bleed Monitoring System is designed to protect, and in some cases, save the lives of patients undergoing an endovascular procedure by allowing physicians to detect the onset of bleeding early and take appropriate steps to address the bleed before detrimental, irreversible, and life-threatening consequences occur."
Saranas is a privately held Houston-based medical device company focused on improving patient outcomes through early detection and monitoring of internal bleeding complications. The company’s patented bleed monitoring system for vascular access procedures enables physicians to mitigate downstream consequences by addressing bleeding complications immediately, improving patient outcomes and lowering healthcare costs. For more information, visit www.saranas.com.